• 1
    Olyaei AJ, De Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384389.
  • 2
    Sehgal S. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17: 660665.
  • 3
    Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative. Pharmacologic properties in vitro and in vivo. Transplantation 1997; 64: 3642.
  • 4
    Schuurman HJ, Cotton S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplant 1997; 64: 3235.
  • 5
    Eisen HJ, Tuzcu EM, Dorent R et al. for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 6
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 7
    Gourishankar S, Halloran PF. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002 Mar; 2: 195200.
  • 8
    Nashan B. The role of Certican™ (everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001; 33: 32153220.
  • 9
    Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4: 23252345.
  • 10
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 3947.
  • 11
    European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391396.
  • 12
    Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 24059.
  • 13
    Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: Practice and trends. Am J Transplant 2004; 4(Suppl 9): 3853.
  • 14
    Vítko S, Margreiter R, Weimar W et al. Everolimus (Certican™) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 15321540.
  • 15
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 16
    Mathew TH, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998; 65: 14501454.
  • 17
    Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 18
    Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244252.
  • 19
    Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, for the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 13321340.
  • 20
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69: 4856.
  • 21
    Kovarik JM, Kaplan B, Silva HT et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 2002; 73: 920925.
  • 22
    Kovarik JM, Kaplan B, Silva HT et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003; 3: 606613
  • 23
    Costa RA, Lansky AJ, Mintz GS et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113116.
  • 24
    Vitko S, Tedesco H, Eris J. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 625635.
  • 25
    Kovarik J. Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today 2004; 40: 101109.
  • 26
    Humar A, Gillingham KJ, Payne WD et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 18791883.
  • 27
    Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm 2003; 60(Suppl 8): S5S8.
  • 28
    Kaplan B, Srinivas TR, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther Drug Monit 2002; 24: 3639.
  • 29
    Meier-Kriesche HU, Steffen BJ, Chu AH et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004; 4: 20582066.
  • 30
    Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28: 153181.
  • 31
    Mota A. Sirolimus: A new option in transplantation. Expert Opin Pharmacother 2005; 6: 479487.